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LETTER TO THE EDITOR 
We thank Prof. Cooper for his comments (2) on our recent article (1), in which he questions the 
rationale for conducting supramaximal verification (Smax) and, indeed, cardiopulmonary exercise 
testing (CPET) in people with cystic fibrosis (CF). Whilst he should be commended on his vision 
to further develop the exercise testing toolkit for use in a clinical setting, this is disparate to the 
aims of our investigation. Specifically, our study focused on the added value of using Smax to 
improve confidence in the measurement of maximal parameters during incremental CPET, a 
procedure recognized and advocated by the European Respiratory and CF Societies (3), due to its 
functional and prognostic evaluative ability.  
Several of Prof. Cooper’s viewpoints are worthy of challenge. Firstly, Prof. Cooper misinterpreted 
our article, to surmise that inaccuracies during incremental testing “can be ‘corrected’ by an 
additional test in which the participant exercises to exhaustion at a supramaximal constant work-
rate” (2). To reiterate the premise of Smax, this recognized concept (5) enables us to 1) confirm a 
maximal effort has been provided or, importantly, 2) demonstrate that an incremental exercise test 
effort was submaximal. Given the reported validity concerns surrounding secondary verification 
criteria (4), this is a simple extension that may “improve the practitioner’s confidence that a true 
maximal effort has been given by the participant” (1). Indeed, we reported a case whereby Smax 
elevated V̇O2peak 24.4% higher than the preceding ‘exhaustive’ incremental cycling test. We 
acknowledge that the cut-off criteria used was based on the typical error for V̇O2max in children and 
adolescents with CF, this threshold (9%) is comparable to the 10% used in Prof. Cooper’s 
calculations, and the data suggested by his simulation model would still not account for such a 
large increase in exercise capacity. 
Prof. Cooper also raises concerns about the safety of Smax. We acknowledge within our paper that 
cases of hypoxemia did occur during Smax, however, the pertinent finding was that its addition did 
not significantly increase the frequency or magnitude of desaturation compared with incremental 
cycling alone. Given the pulmonary consequences of CF, cases of exercise-induced hypoxemia 
will of course occur. However, CPET allows us to identify the exercise intensity at which this 
occurs, which can be “useful in managing their daily life activities and benefiting their health”, a 
recommendation advocated by Prof. Cooper.  
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Lastly, we acknowledge Prof. Cooper’s viewpoint that “adding uncomfortable procedures to an 
already challenging and time consuming test is not likely to advance CPET in clinical research or 
practice”. However, as the evidence supporting the value of Smax continues to grow (5), we feel 
this additional time (of ~ 20 minutes) is time well spent. Furthermore, considering patients’ 
feedback, data from our research group demonstrated that the majority of young people with CF 
(75%) enjoyed CPET with Smax, and completing the test empowered 50% of them to seek advice 
regarding physical activity (4). Therefore, we would conclude that CPET with Smax, when 
interpreted correctly, may actually fit the criteria Prof. Cooper recommends for modern exercise 
testing (2). 
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